caa a22 4500 386356610 CHVBK 20180307111855.0 cr unu---uuuuu 161130e198907 xx s 000 0 eng 10.1017/S0266462300007467 doi S0266462300007467 pii (NATIONALLICENCE)cambridge-10.1017/S0266462300007467 Comparison of Adjuvant Therapies Using Quality-Of-Life Considerations [Elektronische Daten] The benefit for patients with operable breast cancer treated with adjuvant systemic therapy is small, if reduction of early mortality within the context of randomized control trials is used for treatment comparison. One might consider that the 75%-85% of patients who die despite treatment are overtreated, as are patients who remain alive even without therapy within a given time frame. Larger treatment benefits in terms of avoided or delayed breast cancer relapse have been demonstrated even at early phases of follow-up in the vast majority of adjuvant trials. Exposure of all patients to adjuvant therapy at a time at which no symptoms of disease are present is detrimental in terms of quality of life. Based on our assumption that the quality of life of the patient is typically altered both by subjective toxic effects of adjuvant treatment and by the appearance of relapse, we developed a method of comparing treatment effects in terms of time without symptoms of disease and toxicity of treatment (TWiST). Because the impact of treatment on relapse rates appears earlier than survival effects in all adjuvant therapy trials, and because the value of time without relapse in terms of the quality of life of the patients is as yet poorly defined, we have generalized our method of comparing treatment attitudes to include individual qualitative judgment values. The experience gained from integrating quality-of-life issues into clinical trials for breast cancer might also be applied to other diseases characterized by a chronic course, toxic treatments, and gains in periods of relative or absolute freedom from toxic effects and progressive disease. Copyright © Cambridge University Press 1989 Gelber Richard D. Harvard medical School and School of Public Health Dana-Farber Cancer Institute, Boston Goldhirsch A. Ospedale San Giovanni, Bellinzona Ospedale Civico, Lugano Ospedale Beata Vergine, Mendrisio International Journal of Technology Assessment in Health Care Cambridge University Press 5/3(1989-07), 401-413 0266-4623 5:3<401 1989 5 THC https://doi.org/10.1017/S0266462300007467 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1017/S0266462300007467 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Gelber Richard D. Harvard medical School and School of Public Health Dana-Farber Cancer Institute, Boston NATIONALLICENCE 700 1- Goldhirsch A. Ospedale San Giovanni, Bellinzona Ospedale Civico, Lugano Ospedale Beata Vergine, Mendrisio NATIONALLICENCE 773 0- International Journal of Technology Assessment in Health Care Cambridge University Press 5/3(1989-07), 401-413 0266-4623 5:3<401 1989 5 THC CC0 http://creativecommons.org/publicdomain/zero/1.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-cambridge